-
Tytuł:
-
Availability and use of rapid diagnostic tests for the management of acute childhood infections in Europe: A cross-sectional survey of paediatricians.
-
Autorzy:
-
Dewez JE; Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom.; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).
Pembrey L; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Nijman RG; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Department of Infectious Diseases, Section of Paediatric Infectious Diseases, Imperial College London, London, United Kingdom.; Research in European Paediatric Emergency Medicine (REPEM).
Del Torso S; ChildCare WorldWide, Padova, Italy.; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).
Grossman Z; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Adelson School of Medicine, Ariel University, Ariel, Israel.; Pediatric Clinic, Maccabi Healthcare Services, Tel Aviv, Israel.
Hadjipanayis A; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Paediatric Department, Larnaca General Hospital, Larnaca, Cyprus.; Medical School, European University Cyprus, Nicosia, Cyprus.
Van Esso D; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Primary Care Paediatrician, Health Care Centre Pere Grau, Barcelona, Spain.
Lim E; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Great North Children's Hospital, Paediatric Immunology, Infectious Diseases & Allergy, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Emonts M; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Great North Children's Hospital, Paediatric Immunology, Infectious Diseases & Allergy, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Burns J; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Gras-LeGuen C; Centre d'Investigation Clinique CIC1413, INSERM-Nantes University Hospital, Nantes, France.
Kohlfuerst D; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Medical University of Graz, Graz, Austria.
Dornbusch HJ; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Medical University of Graz, Graz, Austria.
Brengel-Pesce K; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; BioMérieux, Lyon, France.
Mallet F; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; BioMérieux, Lyon, France.
von Both U; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; University Hospital, Ludwig Maximilians University (LMU), Munich, Germany.
Tsolia M; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; P. and A. Kyriakou Children's Hospital, Athens, Greece.
Eleftheriou I; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; P. and A. Kyriakou Children's Hospital, Athens, Greece.
Zavadska D; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Children Clinical University Hospital, Riga, Latvia.
de Groot R; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Radboud University Medical Center, Nijmegen, the Netherlands.
van der Flier M; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
Moll H; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Research in European Paediatric Emergency Medicine (REPEM).; Department of General Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
Hagedoorn N; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Department of General Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
Borensztajn D; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Department of General Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
Oostenbrink R; Research in European Paediatric Emergency Medicine (REPEM).; Department of General Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
Kuijpers T; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Amsterdam University Medical Center, Amsterdam, the Netherlands.
Pokorn M; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Department of Infectious Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Vincek K; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Department of Infectious Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Martinón-Torres F; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
Rivero I; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
Agyeman P; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Bern University Hospital, University of Bern, Bern, Switzerland.
Carrol ED; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Alder Hey Children's Hospital, Liverpool, United Kingdom.
Paulus S; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.
Cunnington A; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Department of Infectious Diseases, Section of Paediatric Infectious Diseases, Imperial College London, London, United Kingdom.
Herberg J; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Department of Infectious Diseases, Section of Paediatric Infectious Diseases, Imperial College London, London, United Kingdom.
Levin M; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Department of Infectious Diseases, Section of Paediatric Infectious Diseases, Imperial College London, London, United Kingdom.
Mujkić A; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; University of Zagreb, School of Medicine, Andrija Štampar School of Public Health, Zagreb, Croatia.
Geitmann K; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Primary Care Paediatrician, BVKJ, Hagen, Germany.
Da Dalt L; Research in European Paediatric Emergency Medicine (REPEM).; Department of Woman's and Child's Health Padova University Hospital, Padua, Italy.
Valiulis A; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Vilnius University Medical Faculty, Institute of Clinical Medicine, Clinic of Children's Diseases, Vilnius, Lithuania.
Lapatto R; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Department of Paediatrics, Helsinki University Hospital, Helsinki, Finland.
Syridou G; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Attiko University Hospital, Chaidari, Greece.
Altorjai P; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Association of Hungarian Primary Care Paediatricians, Budapest, Hungary.
Torpiano P; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Department of Paediatrics and Adolescent Health at Mater Dei Hospital, Valletta, Malta.
Størdal K; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Paediatric Research Institute, University of Oslo, Oslo, Norway.
Illy K; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Dutch Society of Paediatrics NVK, Utrecht, the Netherlands.
Mazur A; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Medical College of Rzeszow University, Rzeszów, Poland.
Spreitzer MV; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Zdravstveni dom Domžale, Slovenian Paediatric Society, Burnaby, Slovenia.
Rios J; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Hospital Beatriz Ângelo, Loures, Portugal.
Wyder C; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Kinderärzte KurWerk, Burgdorf, Switzerland.
Romankevych I; European Academy of Paediatrics Research in Ambulatory Settings network (EAPRASnet).; Ukrainian Academy of Pediatric Specialties, Ukraine.
Basmaci R; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Service de Pédiatrie-Urgences, AP-HP, Hôpital Louis-Mourier, Colombes, France.
Ibanez-Mico S; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Yeung S; Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom.; Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management Across the European Union (PERFORM).; Department of Paediatrics, St Mary's Imperial College Hospital, London, United Kingdom.
-
Źródło:
-
PloS one [PLoS One] 2022 Dec 20; Vol. 17 (12), pp. e0275336. Date of Electronic Publication: 2022 Dec 20 (Print Publication: 2022).
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: San Francisco, CA : Public Library of Science
-
MeSH Terms:
-
Rapid Diagnostic Tests*
Point-of-Care Testing*
Infant ; Humans ; Child ; Cross-Sectional Studies ; Pediatricians ; Lactates
-
References:
-
Curr Opin Infect Dis. 2021 Oct 1;34(5):552-558. (PMID: 34232136)
BMJ. 2013 Apr 02;346:f1706. (PMID: 23550046)
Fam Pract. 2005 Aug;22(4):367-74. (PMID: 15897210)
JAMA. 2016 Aug 23-30;316(8):835-45. (PMID: 27552617)
BMJ Open. 2019 Feb 1;9(1):e025036. (PMID: 30782747)
BMJ Paediatr Open. 2019 Jun 27;3(1):e000456. (PMID: 31338429)
BMJ Open. 2021 May 10;11(5):e044510. (PMID: 33972339)
Lancet. 2010 Mar 6;375(9717):834-45. (PMID: 20132979)
Scand J Prim Health Care. 2015;33(4):275-82. (PMID: 26643196)
BMC Infect Dis. 2016 Nov 25;16(1):709. (PMID: 27887585)
Pediatr Res. 2018 Oct;84(4):487-493. (PMID: 29967527)
Scand J Infect Dis. 2010;42(2):90-6. (PMID: 19902992)
Clin Chim Acta. 2014 Jan 1;427:49-57. (PMID: 24076255)
PLoS One. 2020 Jul 6;15(7):e0235605. (PMID: 32628707)
Front Cell Infect Microbiol. 2019 Jun 04;9:196. (PMID: 31275863)
Cochrane Database Syst Rev. 2020 Jun 4;6:CD012431. (PMID: 32497279)
BMJ. 2012 Oct 02;345:e6230. (PMID: 23033411)
Scand J Infect Dis. 2008;40(8):648-54. (PMID: 18979603)
Health Technol Assess. 2006 Oct;10(36):iii-iv, xi-xiii, 1-154. (PMID: 17014747)
Pediatr Res. 2020 Oct;88(4):524-525. (PMID: 32892214)
Scand J Prim Health Care. 2015 Mar;33(1):11-20. (PMID: 25716427)
Scand J Infect Dis. 2004;36(3):213-8. (PMID: 15119368)
Arch Dis Child. 2015 Apr;100(4):341-7. (PMID: 25378379)
Clin Infect Dis. 2019 Jun 18;69(1):24-33. (PMID: 30285232)
An Pediatr (Engl Ed). 2021 Feb;94(2):82-91. (PMID: 32430217)
Value Health. 2017 Apr;20(4):556-566. (PMID: 28407997)
BMC Fam Pract. 2017 Jan 26;18(1):9. (PMID: 28125965)
PLoS Med. 2020 Aug 19;17(8):e1003208. (PMID: 32813708)
J Med Internet Res. 2017 Nov 01;19(11):e367. (PMID: 29092808)
BMJ Open. 2017 Sep 1;7(9):e015760. (PMID: 28864692)
PLoS One. 2016 Apr 27;11(4):e0153778. (PMID: 27120054)
Med Mal Infect. 2009 Jun;39(6):375-81. (PMID: 19345529)
BMJ Open. 2014 Aug 08;4(8):e005611. (PMID: 25107438)
Evid Based Child Health. 2010 Jun;5(2):709-751. (PMID: 32313519)
-
Grant Information:
-
668303 United Kingdom DH_ Department of Health; 848196 United Kingdom DH_ Department of Health
-
Substance Nomenclature:
-
0 (Lactates)
-
Entry Date(s):
-
Date Created: 20221220 Date Completed: 20221222 Latest Revision: 20230109
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC9767335
-
DOI:
-
10.1371/journal.pone.0275336
-
PMID:
-
36538525
-
Background: Point-of-care-tests (POCTs) have been advocated to optimise care in patients with infections but their actual use varies. This study aimed to estimate the variability in the adoption of current POCTs by paediatricians across Europe, and to explore the determinants of variability.
Methods and Findings: A cross-sectional survey was conducted of hospital and primary care paediatricians, recruited through professional networks. Questions focused on the availability and use of currently available POCTs. Data were analysed descriptively and using Median Odds Ratio (MOR) to measure variation between countries. Multilevel regression modelling using changes in the area under the receiver operating characteristic curve of models were used to assess the contribution of individual or workplace versus country level factors, to the observed variation. The commonest POCT was urine dipsticks (UD) which were available to >80% of primary care and hospital paediatricians in 68% (13/19) and 79% (23/29) countries, respectively. Availability of all POCTs varied between countries. In primary care, the country (MOR) varied from 1.61 (95%CI: 1.04-2.58) for lactate to 7.28 (95%CI: 3.04-24.35) for UD. In hospitals, the country MOR varied from 1.37 (95%CI:1.04-1.80) for lactate to 11.93 (95%CI:3.35-72.23) for UD. Most paediatricians in primary care (69%, 795/1154) and hospital (81%, 962/1188) would use a diagnostic test in the case scenario of an infant with undifferentiated fever. Multilevel regression modelling showed that the country of work was more important in predicting both the availability and use of POCTs than individual or workplace characteristics.
Conclusion: There is substantial variability in the adoption of POCTs for the management of acute infections in children across Europe. To inform future implementation of both existing and innovative tests, further research is needed to understand what drives the variation between countries, the needs of frontline clinicians, and the role of diagnostic tests in the management of acute childhood infections.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2022 Dewez et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.
